Latest:
David Lucas Discusses the Bromodomain Inhibitor OTX015
David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David M. Jackman
Latest:
Dr. Jackman on Benefits of Liquid Biopsies in Lung Cancer
David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the benefits of liquid biopsies for patients with lung cancer.
David Maloney, MD, PhD
Latest:
Dr. Maloney on Targets for CAR T-Cell Therapy
David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.
David Morris, MD, FACS
Latest:
Dr Morris on Active Surveillance in Low- and Intermediate-Risk Patients With Prostate Cancer
David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.
David Mutch, MD
Latest:
Dr. Mutch on Frontline Treatment in Endometrial Cancer
David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses frontline treatment for patients with endometrial cancer.